{"product_id":"lucidela-idelalisib","title":"LuciDela (Idelalisib)","description":"\u003ch2\u003eAbout Idelalisib\u003c\/h2\u003e\u003cp\u003eIdelalisib  is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.\u003c\/p\u003e\u003ch3\u003eChronic Lymphocytic Leukemia\u003c\/h3\u003e\u003cp\u003eIndicated, in combination with rituximab, for relapsed chronic lymphocytic leukemia (CLL) in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities\u003c\/p\u003e\u003cp\u003eStarting dose: 150 mg PO BID; continue treatment until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eFollicular B-cell Non-Hodgkin Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for relapsed follicular B-cell non-Hodgkin lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eSmall Lymphocytic Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for small lymphocytic lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003ePneumonitis: Discontinue with any severity of symptomatic pneumonitis\u003c\/p\u003e\u003cp\u003eCrCl ≥15 mL\/min: No dose adjustment required\u003c\/p\u003e\u003ch4\u003eALT\/AST\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;3-5 x ULN: Maintain dose; monitor at least weekly until ≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5-20 x ULN: Withhold idelalisib; monitor ALT\/AST at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eBilirubin\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;1.5-3 x ULN: Maintain dose; monitor at least weekly until≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;3-10 x ULN: Withhold idelalisib; monitor bilirubin at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;10 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eModerate: Maintain dose; monitor at least weekly until resolved\u003c\/li\u003e\n\u003cli\u003eSevere or hospitalization: Withhold idelalisib; monitor at least weekly until resolved, then resume dose at 100 mg BID\u003c\/li\u003e\n\u003cli\u003eLife-threatening: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eNeutropenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eANC 1 to \u0026lt;1.5 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003eANC 0.5 to \u0026lt;1 Gi\/L: Maintain dose; monitor ANC at least weekly\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 Gi\/L: Withhold idelalisib; monitor ANC at least weekly until ANC ≥0.5 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eThrombocytopenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePlatelets 50 to \u0026lt;75 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003ePlatelets 25 to \u0026lt;5 Gi\/L: Maintain dose; monitor platelets at least weekly\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;25 Gi\/L: Withhold idelalisib; monitor platelets at least weekly until platelets ≥25 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfections\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of CMV infection or viremia\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved\u003c\/li\u003e\n\u003cli\u003eIf idelalisib is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade ≥3 sepsis or pneumonia\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eInterrupt idelalisib with until infection has resolved\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of PJP infection\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with suspected PJP infection of any grade\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue idelalisib if PJP infection is confirmed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther severe or life-threatening toxicities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold drug until toxicity is resolved\u003c\/li\u003e\n\u003cli\u003eIf resuming treatment after interruption for other severe or life-threatening toxicities, reduce dose to 100 mg twice daily\u003c\/li\u003e\n\u003cli\u003eDiscontinue idelalisib permanently for recurrence of other severe or life-threatening idelalisib-related toxicity upon rechallenge\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eMonitoring\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMonitor blood counts at least q2 weeks for first 6 months, and at least weekly if neutrophil counts \u0026lt;1x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003eMonitor ALT and AST q2 weeks for first 3 months, q4 weeks for next 3 months, then q1-3 months thereafter\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957701675,"sku":"RL3520250416","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1335.jpg?v=1787022291","url":"https:\/\/xomeds.com\/products\/lucidela-idelalisib","provider":"XOMEDS","version":"1.0","type":"link"}